DE60044041D1 - Exendine zur Glucagon Suppression - Google Patents

Exendine zur Glucagon Suppression

Info

Publication number: DE60044041D1
Authority: DE; Germany
Prior art keywords: exendine; glucagon suppression; exendin; glucagon; suppression
Prior art date: 1999-01-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60044041T

Other languages

English (en)

Inventor

Andrew Young

Bronislava Gedulin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amylin Pharmaceuticals LLC

Original Assignee

Amylin Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-14

Filing date

2000-01-14

Publication date

2010-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27381821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60044041(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-01-14 Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC

2010-04-29 Application granted granted Critical

2010-04-29 Publication of DE60044041D1 publication Critical patent/DE60044041D1/de

2020-01-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

102000051325 Glucagon Human genes 0.000 title abstract 2
108060003199 Glucagon Proteins 0.000 title abstract 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
229960004666 glucagon Drugs 0.000 title abstract 2
230000001629 suppression Effects 0.000 title 1
239000000556 agonist Substances 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

DE60044041T 1999-01-14 2000-01-14 Exendine zur Glucagon Suppression Expired - Lifetime DE60044041D1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US11638099P	1999-01-14	1999-01-14
US13201799P	1999-04-30	1999-04-30
US17536500P	2000-01-10	2000-01-10

Publications (1)

Publication Number	Publication Date
DE60044041D1 true DE60044041D1 (de)	2010-04-29

Family

ID=27381821

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE60032331T Expired - Lifetime DE60032331T2 (de)	1999-01-14	2000-01-14	Exendine zur glucagon suppression
DE60044041T Expired - Lifetime DE60044041D1 (de)	1999-01-14	2000-01-14	Exendine zur Glucagon Suppression

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE60032331T Expired - Lifetime DE60032331T2 (de)	1999-01-14	2000-01-14	Exendine zur glucagon suppression

Country Status (18)

Country	Link
US (3)	US6872700B1 (de)
EP (2)	EP1658856B1 (de)
JP (1)	JP2002538084A (de)
KR (2)	KR20070051948A (de)
CN (1)	CN100425284C (de)
AT (2)	ATE460942T1 (de)
AU (2)	AU770712B2 (de)
BR (1)	BRPI0007823A8 (de)
CA (1)	CA2356331C (de)
CY (1)	CY1106347T1 (de)
DE (2)	DE60032331T2 (de)
DK (1)	DK1143989T3 (de)
ES (2)	ES2278589T3 (de)
HK (1)	HK1046105A1 (de)
NO (3)	NO328077B1 (de)
NZ (1)	NZ512657A (de)
PT (1)	PT1143989E (de)
WO (1)	WO2000041548A2 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2016950B1 (de)	1996-08-08	2011-01-05	Amylin Pharmaceuticals, Inc.	Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
US6703359B1 (en) *	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
KR100637433B1 (ko) *	2004-05-24	2006-10-20	삼성에스디아이 주식회사	발광 표시 장치
US20030087820A1 (en) *	1999-01-14	2003-05-08	Young Andrew A.	Novel exendin agonist formulations and methods of administration thereof
PT1143989E (pt)	1999-01-14	2007-03-30	Amylin Pharmaceuticals Inc	Exendinas para supressão de glucagon
US7399489B2 (en)	1999-01-14	2008-07-15	Amylin Pharmaceuticals, Inc.	Exendin analog formulations
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6924264B1 (en) *	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US20090175821A1 (en) *	1999-05-17	2009-07-09	Bridon Dominique P	Modified therapeutic peptides with extended half-lives in vivo
US6506724B1 (en) *	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
AU2014277804B2 (en) *	2001-07-31	2016-12-01	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Glp-1 exendin-4 peptide analogs and uses thereof
AU2002348469B2 (en) *	2001-10-18	2008-03-13	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
ES2320754T3 (es) *	2002-10-22	2009-05-28	Waratah Pharmaceuticals, Inc.	Tratamiento de la diabetes.
WO2004050115A2 (en) *	2002-12-03	2004-06-17	Novo Nordisk A/S	Combination treatment using exendin-4 and thiazolidinediones
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
KR100733940B1 (ko) *	2003-03-19	2007-06-29	일라이 릴리 앤드 캄파니	폴리에틸렌 글리콜이 연결된 ｇｌｐ-1 화합물
AU2005207870B2 (en) *	2004-01-30	2010-08-19	Waratah Pharmaceuticals, Inc.	The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels
PT2100904E (pt)	2004-04-23	2010-09-24	Conjuchem Biotechnologies Inc	Fase sólida para utilização num método para a purificação de conjugados de albumina
MXPA06015049A (es) *	2004-07-08	2007-02-08	Novo Nordisk As	Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
EP1841448A2 (de) *	2004-12-30	2007-10-10	Diakine Therapeutics, Inc.	Pharmazeutische zusammensetzungen und vefahren zur wiederherstellung der betazellmasse und funktion
US8716221B2 (en) *	2005-01-14	2014-05-06	Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.	Modified exendins and uses thereof
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
US7759312B2 (en) *	2005-03-11	2010-07-20	Endo Pharmaceuticals Solutions Inc.	Delivery of dry formulations of octreotide
EP2457564A1 (de) *	2005-03-11	2012-05-30	Endo Pharmaceuticals Solutions Inc.	Octreotid-Formulierungen mit kontrollierter Freisetzung
WO2007024700A2 (en)	2005-08-19	2007-03-01	Amylin Pharmaceuticals, Inc.	Exendin for treating diabetes and reducing body weight
US8039432B2 (en) *	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
WO2007075534A2 (en)	2005-12-16	2007-07-05	Nektar Therapeutics Al, Corporation	Polymer conjugates of glp-1
JP2009520469A (ja) *	2005-12-22	2009-05-28	コンジュクヘムビオテクフノロギエスインコーポレイテッド	アルブミンと治療薬との前もって形成された抱合体の産生のための方法
DK2020990T3 (da)	2006-05-30	2010-12-13	Intarcia Therapeutics Inc	Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
KR101200728B1 (ko)	2006-08-09	2012-11-13	인타르시아 세라퓨틱스 인코포레이티드	삼투성 전달 시스템 및 피스톤 조립체
CN102827284B (zh) *	2006-11-14	2015-07-29	上海仁会生物制药股份有限公司	带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
KR100805208B1 (ko)	2007-03-27	2008-02-21	주식회사 펩트론	엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
ES2402172T3 (es)	2007-04-23	2013-04-29	Intarcia Therapeutics, Inc	Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
KR20100069651A (ko) *	2007-09-11	2010-06-24	몬도바이오테크 래보래토리즈 아게	Ｈｃｍｖ 감염의 치료를 위한 치료제로서의 ｂｕｂｕｃ 및 임의의 ｅａａ－ｍａｒｔ１（２６－３５）의 용도
CN102026666B (zh) *	2007-12-11	2013-10-16	常山凯捷健生物药物研发（河北）有限公司	促胰岛素肽缀合物制剂
DK2240155T3 (da)	2008-02-13	2012-09-17	Intarcia Therapeutics Inc	Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
WO2009143285A2 (en)	2008-05-21	2009-11-26	Amylin Pharmaceuticals, Inc.	Exendins to lower cholestrol and triglycerides
JP5622725B2 (ja) *	2008-06-25	2014-11-12	エンドファーマスーティカルズソリューションズインコーポレイテッド．ＥｎｄｏＰｈａｒｍａｃｅｕｔｉｃａｌｓＳｏｌｕｔｉｏｎｓｉｎｃ．	エキセナチド及び他のポリペプチド類の持続的送達
AU2009262263B2 (en)	2008-06-25	2014-08-14	Endo Pharmaceuticals Solutions Inc.	Octreotide implant having a release agent
CN104248623B (zh)	2008-09-04	2020-04-03	安米林药品有限责任公司	使用非水性载体的持续释放制剂
CN101870728A (zh)	2009-04-23	2010-10-27	派格生物医药(苏州)有限公司	新型Exendin变体及其缀合物
EP2435061A4 (de)	2009-05-28	2013-03-27	Amylin Pharmaceuticals Inc	Schlaffördernde glp-1-rezeptor-agonistenverbindungen
KR101112578B1 (ko) *	2009-07-16	2012-02-16	성균관대학교산학협력단	엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법
CN101987868B (zh) *	2009-07-30	2013-09-04	江苏豪森医药集团有限公司	Glp-1类似物的衍生物或其可药用盐和用途
RU2753280C2 (ru)	2009-09-28	2021-08-12	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20140066370A1 (en)	2009-11-23	2014-03-06	Amylin Pharmaceuticals, Llc	Polypeptide Conjugate
US9445992B2 (en)	2009-11-25	2016-09-20	Arisgen Sa	Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion
CA2797133C (en)	2010-04-27	2019-08-06	Zealand Pharma A/S	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
JP6121330B2 (ja)	2010-09-28	2017-04-26	アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc	作用持続時間が増した改変ポリペプチド
ES2630031T3 (es)	2010-09-28	2017-08-17	Aegerion Pharmaceuticals, Inc.	Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
JP2014504588A (ja)	2010-12-22	2014-02-24	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2014521594A (ja)	2011-05-25	2014-08-28	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	長持続期間デュアルホルモンコンジュゲート
KR101357117B1 (ko) *	2011-06-28	2014-02-06	비앤엘델리팜 주식회사	폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
ES2732475T3 (es)	2011-07-08	2019-11-22	Aegerion Pharmaceuticals Inc	Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
WO2013009545A1 (en)	2011-07-08	2013-01-17	Amylin Pharmaceuticals, Inc.	Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP6359972B2 (ja)	2011-11-03	2018-07-18	ジーランドファーマアクティーゼルスカブ	Ｇｌｐ−１受容体アゴニストペプチドガストリンコンジュゲート
US9745359B2 (en)	2012-05-18	2017-08-29	Adda Biotech Inc.	Protein and protein conjugate for diabetes treatment, and applications thereof
MX2014015557A (es)	2012-06-21	2015-02-24	Univ Indiana Res & Tech Corp	Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
AR091866A1 (es)	2012-07-23	2015-03-04	Zealand Pharma As	Analogos del glucagon
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211231A1 (en)	2012-12-21	2016-05-20	Sanofi	Exendin-4 derivatives
CN119119233A (zh)	2013-10-17	2024-12-13	西兰制药公司	酰化胰高血糖素类似物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
US10093713B2 (en)	2013-11-06	2018-10-09	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
WO2015067716A1 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Glucagon-glp-1-gip triple agonist compounds
WO2015081891A1 (en)	2013-12-06	2015-06-11	Baikang (Suzhou) Co., Ltd	Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080154B1 (de)	2013-12-13	2018-02-07	Sanofi	Duale glp-1/gip-rezeptoragonisten
CN106029087A (zh)	2013-12-20	2016-10-12	印第安纳大学研究及科技有限公司	脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
WO2015138638A1 (en)	2014-03-11	2015-09-17	Theraly Pharmaceuticals, Inc.	Long acting trail receptor agonists for treatment of autoimmune diseases
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) *	2014-08-21	2016-01-27	Дафот Энтерпрайсис Лимитед	Пептид для лечения сахарного диабета 2-го типа и его осложнений
GB201415598D0 (en)	2014-09-03	2014-10-15	Univ Birmingham	Elavated Itercranial Pressure Treatment
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2015340586B2 (en)	2014-10-29	2020-04-30	Zealand Pharma A/S	GIP agonist compounds and methods
KR20170137198A (ko)	2015-04-16	2017-12-12	질랜드 파마 에이/에스	아실화된 글루카곤 유사체
ES2887723T3 (es)	2015-05-22	2021-12-27	Univ Leland Stanford Junior	Tratamiento de hipoglucemia posbariátrica con exendina(9-39)
KR101661332B1 (ko)	2015-05-28	2016-09-29	(의료)길의료재단	글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
KR102650751B1 (ko)	2015-06-03	2024-03-22	인타르시아 세라퓨틱스 인코포레이티드	임플란트 배치 및 제거 시스템들
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP7026044B2 (ja)	2015-12-23	2022-02-25	ザ・ジョンズ・ホプキンス・ユニバーシティー	神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ－１ｒアゴニスト
SG11201805255TA (en)	2015-12-23	2018-07-30	Amgen Inc	Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
SG11201807832VA (en) *	2016-03-16	2018-10-30	Prolynx Llc	Extended release conjugates of exenatide analogs
TWI814219B (zh)	2016-05-16	2023-09-01	美商因塔希亞治療公司	升糖素受體選擇性多肽和彼之使用方法
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
EP3515408A1 (de)	2016-09-23	2019-07-31	Delpor, Inc.	Stabile zusammensetzungen für inkretin-mimetische verbindungen
BR112019010236A2 (pt)	2016-11-21	2019-08-20	Eiger Biopharmaceuticals Inc	formulações tamponadas de exendina (9-39)
WO2018104263A1 (en)	2016-12-06	2018-06-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
AU2017371516C1 (en)	2016-12-09	2021-09-02	Zealand Pharma A/S	Acylated GLP-1/GLP-2 dual agonists
WO2018115401A1 (en) *	2016-12-22	2018-06-28	Sanofi	Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US10835580B2 (en)	2017-01-03	2020-11-17	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
JOP20190177A1 (ar)	2017-01-17	2019-07-16	Amgen Inc	طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
EA201992502A1 (ru)	2017-06-20	2020-04-22	Эмджен Инк.	Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
JP7536030B2 (ja)	2019-03-08	2024-08-19	アムジエン・インコーポレーテツド	増殖分化因子１５併用療法
CN110151980B (zh) *	2019-06-30	2022-12-09	中国药科大学	Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
WO2022266467A2 (en)	2021-06-17	2022-12-22	Dana-Farber Cancer Institute, Inc.	Recombinant histone polypeptide and uses thereof
WO2024123812A1 (en)	2022-12-05	2024-06-13	Shattuck Labs, Inc.	Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US5264372A (en)	1991-03-15	1993-11-23	Amylin Pharmaceuticals, Inc.	Receptor-based screening methods for amylin agonists and antagonists
US5452284A (en) *	1992-09-14	1995-09-19	Matsushita Electric Industrial Co., Ltd.	Optical recording/reproducing medium and apparatus using land and groove encoded information signals and identification signals including position information
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
KR100429966B1 (ko)	1993-09-07	2004-05-04	아밀린 파마슈티칼스, 인크.	위장 운동성 조절을 위한 제약 조성물
US5726969A (en) *	1994-12-28	1998-03-10	Matsushita Electric Industrial Co., Ltd.	Optical recording medium having dual information surfaces
CN100342443C (zh) *	1995-10-09	2007-10-10	松下电器产业株式会社	光盘条形码形成方法和光盘重放装置
KR100460398B1 (ko) *	1995-10-09	2005-01-17	마쯔시다덴기산교 가부시키가이샤	광디스크
EP0786767B1 (de) *	1996-01-26	2005-03-16	Sharp Kabushiki Kaisha	Optisches Aufzeichnungsmedium und Optische Aufzeichnungs- Wiedergabevorrichtung und Verfahren zur Herstellung eines optischen Aufzeichnungsmediums
US5883958A (en) *	1996-04-01	1999-03-16	Sony Corporation	Method and device for data decryption, a method and device for device identification, a recording medium, a method of disk production, and a method and apparatus for disk recording
US5839443A (en) *	1996-05-16	1998-11-24	The Trustees Of Columbia University In The City Of New York	Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
JP2856390B2 (ja) *	1996-07-26	1999-02-10	株式会社日立製作所	情報記録媒体及びそれを用いた記録再生方法
CN1183158C (zh)	1996-06-05	2005-01-05	罗赫诊断器材股份有限公司	Exendin类似物,其制备方法及含有它们的药物制剂
US5686511A (en)	1996-06-28	1997-11-11	The Valspar Corporation	Esterifying epoxy resin with carboxyl polymer and quenching
DE69738507T2 (de) *	1996-07-10	2008-06-12	Hitachi, Ltd.	Verfahren und System zum Datenzugriff für einen optischen Plattenspieler
EP2016950B1 (de)	1996-08-08	2011-01-05	Amylin Pharmaceuticals, Inc.	Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
CN1311457C (zh) *	1996-12-19	2007-04-18	松下电器产业株式会社	光盘再生装置
DE69831673C5 (de)	1997-01-07	2015-01-22	Amylin Pharmaceuticals, Llc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US6051557A (en) *	1997-05-16	2000-04-18	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
JPH1131357A (ja) *	1997-07-08	1999-02-02	Pioneer Electron Corp	情報データの記録方法
US6753165B1 (en) *	1999-01-14	2004-06-22	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
BR9811866A (pt)	1997-08-08	2000-08-15	Amylin Pharmaceuticals Inc	Compostos agonistas de exendina
JPH11196084A (ja) *	1997-10-31	1999-07-21	Matsushita Electric Ind Co Ltd	暗号化システム
ATE383867T1 (de)	1997-11-14	2008-02-15	Amylin Pharmaceuticals Inc	Neuartige exendin agonisten
BR9815670A (pt)	1997-11-14	2000-10-17	Amylin Pharmaceuticals Inc	Compostos agonistas de exendina
AU759058C (en)	1998-02-13	2005-09-15	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
US6376549B1 (en) *	1998-09-17	2002-04-23	Akesis Pharmaceuticals, Inc.	Metforimin-containing compositions for the treatment of diabetes
PT1143989E (pt)	1999-01-14	2007-03-30	Amylin Pharmaceuticals Inc	Exendinas para supressão de glucagon
ES2244416T5 (es)	1999-01-14	2020-01-03	Amylin Pharmaceuticals Llc	Formulaciones novedosas de agonistas de la exendina y métodos de administración de los mismos
US6451974B1 (en) *	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
US6924264B1 (en) *	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6519213B1 (en) *	1999-06-29	2003-02-11	Oak Technology, Inc.	Method and apparatus for reading data from a disk

2000
- 2000-01-14 PT PT00902415T patent/PT1143989E/pt unknown
- 2000-01-14 ES ES00902415T patent/ES2278589T3/es not_active Expired - Lifetime
- 2000-01-14 DK DK00902415T patent/DK1143989T3/da active
- 2000-01-14 NZ NZ512657A patent/NZ512657A/xx not_active IP Right Cessation
- 2000-01-14 WO PCT/US2000/000942 patent/WO2000041548A2/en not_active Application Discontinuation
- 2000-01-14 EP EP06002683A patent/EP1658856B1/de not_active Expired - Lifetime
- 2000-01-14 CN CNB008050171A patent/CN100425284C/zh not_active Expired - Lifetime
- 2000-01-14 AT AT06002683T patent/ATE460942T1/de not_active IP Right Cessation
- 2000-01-14 JP JP2000593169A patent/JP2002538084A/ja active Pending
- 2000-01-14 AU AU24136/00A patent/AU770712B2/en not_active Expired
- 2000-01-14 ES ES06002683T patent/ES2343072T3/es not_active Expired - Lifetime
- 2000-01-14 AT AT00902415T patent/ATE347901T1/de active
- 2000-01-14 CA CA002356331A patent/CA2356331C/en not_active Expired - Lifetime
- 2000-01-14 BR BRPI0007823A patent/BRPI0007823A8/pt not_active Application Discontinuation
- 2000-01-14 EP EP00902415A patent/EP1143989B1/de not_active Expired - Lifetime
- 2000-01-14 KR KR1020077009281A patent/KR20070051948A/ko not_active Ceased
- 2000-01-14 DE DE60032331T patent/DE60032331T2/de not_active Expired - Lifetime
- 2000-01-14 HK HK02107813.8A patent/HK1046105A1/zh unknown
- 2000-01-14 KR KR1020017008892A patent/KR20020001719A/ko not_active Ceased
- 2000-01-14 DE DE60044041T patent/DE60044041D1/de not_active Expired - Lifetime
- 2000-01-14 US US09/889,331 patent/US6872700B1/en not_active Expired - Lifetime
2001
- 2001-07-12 NO NO20013469A patent/NO328077B1/no not_active IP Right Cessation
2004
- 2004-05-26 AU AU2004202293A patent/AU2004202293B2/en not_active Expired
2005
- 2005-03-18 US US11/083,730 patent/US7153825B2/en not_active Expired - Lifetime
2006
- 2006-10-19 US US11/584,114 patent/US7407932B2/en not_active Expired - Fee Related
2007
- 2007-03-01 CY CY20071100286T patent/CY1106347T1/el unknown
2010
- 2010-05-11 NO NO2010010C patent/NO2010010I1/no not_active Application Discontinuation
- 2010-05-20 NO NO2010012C patent/NO2010012I1/no unknown

Also Published As

Publication number	Publication date
NZ512657A (en)	2004-01-30
NO20013469L (no)	2001-09-14
HK1046105A1 (zh)	2002-12-27
US6872700B1 (en)	2005-03-29
NO2010010I1 (no)	2010-06-07
US7407932B2 (en)	2008-08-05
EP1658856A1 (de)	2006-05-24
ATE460942T1 (de)	2010-04-15
ES2343072T3 (es)	2010-07-22
ATE347901T1 (de)	2007-01-15
WO2000041548A2 (en)	2000-07-20
CA2356331C (en)	2009-10-13
NO20013469D0 (no)	2001-07-12
EP1143989A3 (de)	2002-09-11
BRPI0007823A8 (pt)	2017-03-21
AU770712B2 (en)	2004-02-26
CY1106347T1 (el)	2011-10-12
WO2000041548A3 (en)	2001-11-29
NO328077B1 (no)	2009-11-23
US7153825B2 (en)	2006-12-26
CA2356331A1 (en)	2000-07-20
CN1347327A (zh)	2002-05-01
KR20020001719A (ko)	2002-01-09
AU2413600A (en)	2000-08-01
JP2002538084A (ja)	2002-11-12
EP1658856B1 (de)	2010-03-17
ES2278589T3 (es)	2007-08-16
BR0007823A (pt)	2001-11-20
DE60032331T2 (de)	2007-06-21
DK1143989T3 (da)	2007-04-16
PT1143989E (pt)	2007-03-30
US20070037750A1 (en)	2007-02-15
KR20070051948A (ko)	2007-05-18
AU2004202293B2 (en)	2007-09-20
NO2010012I1 (no)	2010-06-07
US20050171019A1 (en)	2005-08-04
DE60032331D1 (de)	2007-01-25
AU2004202293A1 (en)	2004-06-17
EP1143989A2 (de)	2001-10-17
EP1143989B1 (de)	2006-12-13
CN100425284C (zh)	2008-10-15

Publication	Publication Date	Title
ATE347901T1 (de)	2007-01-15	Exendine zur glucagon suppression
EE200300212A (et)	2003-08-15	Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
DE60014279D1 (de)	2004-11-04	Stiftförmige Medikamentenspritze
MXPA03006884A (es)	2003-11-13	Formulacion farmaceutica.
DK1414486T3 (da)	2010-08-30	Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme
WO2003072195A3 (en)	2004-03-25	Method for administering glp-1 molecules
EP1405859A4 (de)	2008-01-23	Nitrogenes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung, dessen medizinische verwendung und zwischenprodukt dafür
AU2003299849A1 (en)	2004-07-22	Drug delivery apparatus
MXPA03007641A (es)	2003-12-04	Formulacion farmaceutica.
IS7691A (is)	2005-02-09	Lyfjasamsetningar til að meðhöndla æxli
AU2003220956A1 (en)	2003-10-20	Insulin administration apparatus
AU2001256373A1 (en)	2003-02-06	Syringe and method for the use thereof
IL159576A0 (en)	2004-06-01	Pharmaceutical formulation for the intramuscular administration of fulvestrant
DE60217390D1 (de)	2007-02-15	Bicalutamid enthaltende pharmazeutische zusammensetzung
ZA200309513B (en)	2004-12-08	Novel heterocyclic derivatives and medicinal use thereof.
GB9907571D0 (en)	1999-05-26	Compounds
AU2002368133A1 (en)	2004-02-16	1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
HRP20080597T3 (en)	2008-12-31	Cancer combination therapy comprising azd2171 and zd1839
DE69934902D1 (de)	2007-03-08	Medikament gegen drogenabhängigkeit
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
ATE350029T1 (de)	2007-01-15	Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
GB0212790D0 (en)	2002-07-10	Medicament for the treatment of diabetes
GB0201607D0 (en)	2002-03-13	Formulation for the administration of medicinal substances
HUP0600455A2 (en)	2006-09-28	Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes
SE0000332D0 (sv)	2000-01-31	New use

Legal Events

Date	Code	Title	Description
2011-04-07	8364	No opposition during term of opposition